Johnson & Johnson Is Doing A Phase 3 Vaccine Trial Which Could Mean Doses For Canada
It could be ready for emergency use in early 2021.
This sounds promising. A COVID-19 vaccine is moving into a phase three trial which could mean that it might be approved for production and use soon. While this vaccine is being developed by a U.S. company, there's a Canadian connection.
Johnson & Johnson announced that the vaccine it has been working on is now going into a large-scale, multi-country phase three trial.
Results from the other phases were positive so now it's taking the next step.
Up to 60,000 volunteers from three different continents will take part in this study to see the safety and effectiveness of a single vaccine dose when it comes to preventing COVID-19.
Those volunteers will be over 18 years old with a lot of representation of people over the age of 60.
It's a randomized, double-blind, placebo-controlled clinical trial which means that who gets the vaccine versus a placebo is chosen at random and nobody knows who gets what.
The goal is to eventually make one billion doses of a vaccine every single year.
Johnson & Johnson also wants it to be affordable and be available for emergencies.
The first batches of it could be ready for emergency use authorization in early 2021 if the trial proves it to be both safe and effective.
There is a Canadian connection with this vaccine.
The federal government has signed deals with multiple companies that are working on one right now including Johnson & Johnson.
There are also agreements with Moderna, Pfizer, and Novavax.
Anita Anand, the Minister of Public Services and Procurement, announced new agreements with Sanofi and GlaxoSmithKline on September 22.
Back in August, the deals that had been reached then added up tofor Canada.
That's nowand it's about four times the country's population.
According to the Public Health Agency of Canada, the country isand staying on this path could mean 5,000 daily cases in October.